Skip to main content
ATTO logo

Attovia Therapeutics, Inc. (ATTO) Stock: Price, Forecast & Analyst Target

Attovia Therapeutics, Inc. (ATTO) — MoonshotScore 32/100 (Weak band), calculated Nov 18, 2026. Price $15.53 (+4.51%), as of the Nov 18, 2026 trading session; market cap $710M.

Educational signal · not a buy or sell recommendation · How to read this

$15.53 +$0.67 (+4.51%) Market Cap $710M

Attovia Therapeutics, Inc. · ATTO · NASDAQ

Atento S.A. is a customer relationship management and business process outsourcing (CRM BPO) services provider. It operates across Brazil, the Americas, Europe, the Middle East, and Africa, offering front and back-end services through digital and voice channels.

Price as of Nov 18, 2026

Key Statistics

32 of 100

MoonshotScore v2 · Attovia Therapeutics (ATTO)

Weak
Business Quality Poor (16)
Financial Safety Fortress (94)
Valuation Rich (36)
Growth Durability Shrinking (16)
Momentum Quiet (40)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A fortress balance sheet, but bottom-tier quality, stalling growth and an expensive valuation. The score also carries a risk penalty for being loss-making and burning cash. Business Quality: Poor; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Shrinking; Momentum: Quiet.

Holding back: weak fundamentals, soft growth

Helping: balance-sheet strength

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ATTO (57 recorded, newest six shown)
RecordedScoreBand
32Weak
32Weak
32Weak
32Weak
32Weak
32Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$15.53
Change on the day+4.51%
52-week range$12.94 – $28.00
Market capitalisation$710M—
Shares traded on the day337.2K

Price & events

Other perspectives

Council score for Attovia Therapeutics (ATTO): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Negative
Financial Safety Strong
Valuation Weak
Growth Durability Negative
Momentum Neutral

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Debt/Equity Strong
Gross Margin Negative

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Attovia Therapeutics (ATTO), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Attovia Therapeutics, Inc. (ATTO) is listed on NASDAQ. It employs 44 people and is led by Tao Fu. The market values it at $710M.

3 · Financial strengths and risks

What are the financial strengths and risks for Attovia Therapeutics (ATTO)?

Short answer

The MoonshotScore pillars rate balance-sheet strength as strengths. What is holding it back is weak fundamentals, soft growth. Trailing ratios: current ratio 9.39.

4 · What to check next?

What should you watch next at Attovia Therapeutics (ATTO)?

Short answer · as of

Current published price targets run low $39.00 · high $52.00 · consensus $45.33 · median $45.00 against a quoted price of $15.53 (as of Nov 18, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • No Altman Z or Piotroski screen is held for this filer.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Attovia Therapeutics compare with its peers?

Short answer

Attovia Therapeutics's score ranks 11th of 11 in the bounded comparison shown, against 10 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.28 Nov 18, 2026$552M91 5-pillar Nov 18, 2026
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$12.48 Nov 18, 2026$884M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.30 Nov 18, 2026$546M68 5-pillar Nov 18, 2026
SpyGlass Pharma, Inc. Common Stock (SGP) Same industry, near in market value$29.68 Nov 18, 2026$993M64 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$8.32 Nov 18, 2026$813M63 5-pillar Nov 18, 2026
Cybin Inc. (HELP) Same industry, near in market value$6.89 Nov 18, 2026$550M60 5-pillar Nov 18, 2026
Indaptus Therapeutics, Inc. (INDP) Same industry, near in market value$3.29 Nov 18, 2026$505M60 5-pillar Nov 18, 2026
Alto Neuroscience, Inc. (ANRO) Same industry, near in market value$25.91 Nov 18, 2026$1.04B60 5-pillar Nov 18, 2026
Attovia Therapeutics (ATTO) — this page$15.53$710M32
Ault Alliance, Inc. (AULT) Named competitor$0.21 Sep 11, 2026$8.35M— Model unavailable
CEA Industries Inc. (CEAD) Named competitor$10.00 Sep 11, 2026$8.02M— Model unavailable

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$39.00 – $52.00
Consensus target
$45.33
Median target
$45.00

Consensus record · Captured .

Measured against a quoted price of $15.53 (as of Nov 18, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ATTO in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ATTO in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Attovia Therapeutics (ATTO)?

Read these with our analysis →

Common Questions About ATTO

These answers are editorial: 1 of these 9 answers is drawn from the ATTO research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for ATTO?

ATTO carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Atento S.A. is a customer relationship management and business process outsourcing (CRM BPO) services provider.

Is ATTO a good stock to buy?

Stock Expert AI does not rate ATTO buy, sell or hold. Attovia Therapeutics, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the ATTO stock price today?

The last price recorded for Attovia Therapeutics, Inc. (ATTO), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the ATTO price target?

The analyst consensus price target for Attovia Therapeutics, Inc. (ATTO), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What do analysts say about ATTO stock?

Analyst coverage of Atento S.A. (ATTO) is limited, reflecting its small market capitalization and financial challenges. Key valuation metrics, such as the negative P/E ratio, suggest the company is currently not profitable.

What are the key factors to evaluate for ATTO?

Attovia Therapeutics, Inc. (ATTO) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Acquisitions can provide access to new markets and customer segments. Not financial advice.

How frequently does ATTO data refresh on this page?

ATTO's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven ATTO's recent stock price performance?

Attovia Therapeutics, Inc. (ATTO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Global presence in multiple regions. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ATTO overvalued or undervalued right now?

Attovia Therapeutics, Inc. (ATTO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 8 from Financial Modeling Prep (FMP), 5 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.